Posted by Michael Wonder on 22 Jun 2024
NICE enables access to first treatment that targets the underlying pathophysiology of rare disease X-linked hypophosphataemia in adults
21 June 2024 - Kyowa Kirin is delighted by the decision made today by NICE to recommend Crysvita for the treatment of adults living with X-linked hypophosphataemia in England, Wales and Northern Ireland.
Adults living with the rare disease X-linked hypophosphataemia (XLH) in England, Wales and Northern Ireland will now have access to the first available treatment to tackle the underlying cause of XLH following NICE’s decision to recommend burosumab (marketed as Crysvita) to treat adults who have a confirmed diagnosis of XLH, following a new access deal.
